Equity research analysts tracking NRx Pharmaceuticals (NASDAQ: NRXP) maintain cautious stances, closely monitoring its clinical-stage drug candidates in psychiatry and respiratory diseases. Observers weigh potential regulatory milestones and partnership updates against historical operational losses, micro-cap share volatility, and continuous requirements for capital raises to fund clinical development pipelines.